ClinicalTrials.gg
RecruitingNCT07219407Updated Jan 23, 2026

A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures

A Phase 2 interventional study of RAP-219 in Focal Epilepsy, Epilepsy and Refractory Focal Epilepsy, sponsored by Rapport Therapeutics Inc.. Recruiting at 7 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-01-23.

Sponsored by Rapport Therapeutics Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 102 studies in Epilepsies, Partial with a site in United States — 18 open to participants now, 24 under way, 6 of them phase 3. Epilepsies, Partial · United States.

Planned enrollment
63rd of 86
30 · median 100
Started
2025
with 3 others
Phase 2
23 of 102
4 open now
Primary completion
2028-02
later than 14 of 22 live
Registered
96th of 102
by date
Lead sponsor
4 of 102
Rapport Therapeutics Inc.

Among the 102 studies in Epilepsies, Partial with a site in United States, this one is the 63rd largest by planned enrollment of the 86 interventional ones that give a count, is one of 4 that started in 2025, is one of 23 in phase 2, reaches primary completion later than 14 of the 22 other live ones, and was the 96th registered.

Epilepsies, Partial

243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.

Browse Epilepsies, Partial studies →

Open to participants now

18 of the 102 studies in Epilepsies, Partial with a site in United States are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 37 Epilepsies, Partial studies recruiting now, 9 (24%) set no upper age limit and 24 (65%) stop at 75 or younger; 17 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 102 studies in Epilepsies, Partial with a site in United States, or all of them as a file.
02

Study summary

This is a clinical research study for an investigational drug called RAP-219 in patients with Refractory Focal Epilepsy. This study is being conducted to determine RAP-219 Long- term safety and open-label antiseizure activity in patients with Refractory Focal Epilepsy.

Read the detailed description

This is a multi-center, open-label study to evaluate the long-term safety, tolerability, pharmacokinetics, pharmacodynamics and antiseizure activity of RAP-219 in adult participants with refractory focal seizures

03

Conditions studied

  • Focal Epilepsy
  • Epilepsy
  • Refractory Focal Epilepsy
  • Seizure
  • Focal Seizure
  • Focal Onset Seizure

Keywords

  • Focal Seizures
  • Epilepsy
  • RNS
  • Long episode
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Completion of the associated parent study (RAP-219-FOS-201) treatment period with acceptable tolerability, per Investigator.
  • Diagnosis of focal epilepsy
  • Stable RNS(c) system settings
  • A demonstrated history of compliance with RNS(c) system data interrogation and upload
  • Good overall health other than focal epilepsy, per Investigator.
  • ≥ 18 kg/m\^2 and ≤ 45 kg/m\^2
  • Willing and able to adhere to all aspects of the protocol.

Exclusion criteria

Exclusion Criteria:

  • Known of to RAP-219
  • Any clinically unstable or serious medical, neurological (other than epilepsy), psychological, or behavioral problem; laboratory or finding that would increase participant risk or should otherwise exclude the patient from participation, as assessed by Investigator
  • Pregnancy, lactation, or individuals of who do not agree to simultaneously use two effective birth-control methods
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    RAP-219

    Drug: RAP-219

Interventions

  • Participants will receive one RAP-219 0.125 mg capsule daily for 3 days followed by one 0.25mg tablet RAP-219 daily for 28 days, then one 0.75mg tablet daily for the remainder of the treatment period.

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-emergent adverse events (TEAEs)

    Time frame: From the start of RAP-219 treatment through 8 weeks after last dose, up to Week 112

Secondary outcomes

  1. Percent change in clinical seizure frequency

    Group median percent change in clinical seizure frequency per 28-day period as reported in a clinical seizure diary

    Time frame: Throughout the open-label period until 8 weeks after the last dose, up to Week 112, compared to the pre-treatment baseline period.

  2. Clinical seizure 25%, 50%, 75%, and 100% responder proportions

    Proportion of participants with at least 25%, 50%, 75%, or with 100% reduction in clinical seizure frequency per 28-day period as reported in a clinical seizure diary

    Time frame: Throughout the open-label period until 8 weeks after the last dose, up to Week 112, compared to the pre-treatment baseline period.

  3. Change in clinical seizure-free day frequency

    Group median change in clinical seizure-free day frequency per 28-day period as reported in a clinical seizure diary

    Time frame: Throughout the open-label period until 8 weeks after the last dose, up to Week 112, compared to the pre-treatment baseline period.

  4. Longest clinical seizure-free interval

    Duration, in days, of the longest continuous period of clinical seizure-free days per period as reported in a clinical seizure diary

    Time frame: Throughout the open-label period until 8 weeks after the last dose, up to Week 112, compared to the pre-treatment baseline period.

  5. Time to pre-randomization clinical seizure count

    Duration, in days, between the beginning of the open-label treatment period and the nth clinical seizure, where n is the number of clinical seizures per 28-day period during the prospective pre-treatment baseline period, as reported in a clinical seizure diary

    Time frame: Throughout the open-label period until 8 weeks after the last dose, up to Week 112, compared to the pre-treatment baseline period.

  6. RNS long episode 30%, 50%, 75% or with 100% responder proportions

    Proportion of participants with at least 30%, 50%, 75%, and 100% reduction in long episodes per 28-day period as recorded by the RNS® System

    Time frame: Throughout the open-label period until 8 weeks after the last dose, up to Week 112, compared to the pre-treatment baseline period.

  7. Percent change in RNS long episode frequency

    Group median percent change in long episode frequency per 28-day period as recorded by the RNS® System

    Time frame: Throughout the open-label period until 8 weeks after the last dose, up to Week 112, compared to the pre-treatment baseline period.

  8. Change in RNS long episode-free day frequency

    Group median change in long episode-free day frequency per 28-day period as recorded by the RNS® System

    Time frame: Throughout the open-label period until 8 weeks after the last dose, up to Week 112, compared to the pre-treatment baseline period.

  9. Longest RNS long episode-free interval

    Duration, in days, of the longest continuous period of long episode-free days per period as recorded by the RNS® System

    Time frame: Throughout the open-label period until 8 weeks after the last dose, up to Week 112, compared to the pre-treatment baseline period.

  10. Time to pre-randomization long episode count

    Duration, in days, between the beginning of the open-label treatment period and the mth long episode, where m is the number of long episodes per 28-day period during the pre-treatment baseline period, as recorded by the RNS® System

    Time frame: Throughout the open-label period until 8 weeks after the last dose, up to Week 112, compared to the pre-treatment baseline period.

  11. Percent change in RNS estimated electrographic seizure frequency

    Group median percent change in estimated electrographic seizure frequency per 28-day period as recorded by the RNS® System

    Time frame: Throughout the open-label period until 8 weeks after the last dose, up to Week 112, compared to the pre-treatment baseline period.

  12. Clinical Global Impression of Change (CGI-C) responder count and proportions

    Count and proportion of participants with any improvement (minimally improved, much improved, or very much improved) or clinically meaningful improvement (much improved or very much improved) as reported on the Clinical Global Impression of Change (CGI-C) scale

    Time frame: Throughout the open-label period until 8 weeks after the last dose, up to Week 112, compared to the pre-treatment baseline period.

  13. Patient Global Impression of Change [PGI-C] responder count and proportions

    Count and proportion of participants with any improvement (minimally improved, much improved, or very much improved) or clinically meaningful improvement (much improved or very much improved) as reported on the Patient Global Impression of Change (PGI-C) scale

    Time frame: Throughout the open-label period until 8 weeks after the last dose, up to Week 112, compared to the pre-treatment baseline period.

07

Study locations

7 of 7 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Feb 2028, 25 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2025
First posted
Oct 21, 2025
StartActual
Dec 15, 2025
Primary completionEst.
Feb 3, 2028
CompletionEst.
Feb 3, 2028
Last update
Jan 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07219407
Lead sponsor
Rapport Therapeutics Inc.
Responsible party
Sponsor
First posted
Oct 21, 2025
Start date
Dec 15, 2025
Primary completion
Feb 3, 2028 (estimated)
Completion
Feb 3, 2028 (estimated)
Last update
Jan 23, 2026

Study contacts

Daniela Moreno
Contact
dmoreno@rapportrx.com
(857) 323-9048
Beth Bowers
Contact
bbowers@rapportrx.com
(857) 323-9048
Imran Quraishi, MD
principal investigator · Yale University

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: RAP-219

Start the discussion